What type of study is this?

This is a Literature Review study.

September 10, 2025Heart Lung and CirculationOpen Access

Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond

View Full Paper

Ask AI

Bookmark

SGLT-2 inhibitors and GLP-1 receptor agonists improve outcomes in cardiovascular disease and chronic kidney disease.
Recent therapies have shown strong evidence for their benefits in managing type 2 diabetes and obesity.
Comparative analysis reveals distinct benefits of emerging therapies alongside established pharmacotherapies.
The increasing complexity of real-world applications raises considerations for effective treatment strategies.

No takes yet. Share an insight, caveat, or question.

This review explores SGLT-2 inhibitors and GLP-1 receptor agonists, highlighting their efficacy in CKM syndrome.

Allahwala et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark